Novartis Gets EC Approval For Cosentyx Label Update In Europe - Quick Facts

Shutterstock photo

(RTTNews.com) - Swiss drug major Novartis AG ( NVS ) announced Friday that the European Commission or EC has approved a label update for Cosentyx (secukinumab).

Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A(IL-17A), in psoriatic arthritis or PsA. The new label update includes dosing flexibility of up to 300 mg based on clinical response that will provide clinicians with greater choice for their patients.

The label update also includes 24-week structural data with subcutaneous regimens demonstrating that Cosentyx inhibits progression of joint damage in PsA.

"Cosentyx has shown that it can slow the progression of joint damage inflicted by psoriatic arthritis, which can lead to significant mobility loss for patients," said Paul Emery Professor of Rheumatology, Arthritis Research UK and Director Leeds NIHR Biomedical Research Centre.

This label update is significant as PsA can lead to significant mobility loss and irreversible joint damage if sub-optimally-treated. PsA is a chronic, progressive and irreversible disease leading to pain, fatigue, as well as activity impairment and significant mobility loss due to structural damage.

The label update is applicable to all European Union and European Economic Area countries and is effective immediately.

To date, Cosentyx has been prescribed to more than 160,000 patients worldwide.

Read the original article on RTTNews (http://www.rttnews.com/2947933/novartis-gets-ec-approval-for-cosentyx-label-update-in-europe-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks , Commodities
Referenced Symbols: NVS

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?